Posaconazole
- Generic Name
- Posaconazole
- Brand Names
- Noxafil, Posanol, Posaconazole Accord, Posaconazole AHCL
- Drug Type
- Small Molecule
- Chemical Formula
- C37H42F2N8O4
- CAS Number
- 171228-49-2
- Unique Ingredient Identifier
- 6TK1G07BHZ
- Background
Posaconazole is a triazole antifungal drug that is used to treat invasive infections by Candida species and Aspergillus species in severely immunocompromised patients.
- Indication
For prophylaxis of invasive Aspergillus and Candida infections in patients, 13 years of age and older, who are at high risk of developing these infections due to being severely immunocompromised as a result of procedures such as hematopoietic stem cell transplant (HSCT) recipients with graft-versus-host disease (GVHD), or due to hematologic malignancies with...
- Associated Conditions
- Candidiasis, Coccidioidomycosis, Esophageal Candidiasis, Fungal Infections, Invasive Aspergillosis, Invasive bronchopulmonary aspergillosis, Mucormycosis, Oropharyngeal Candidiasis, Prophylaxis of Aspergillus infection, Pulmonary cryptococcosis infection
- Associated Therapies
- -
Pharmacokinetics and Safety of Intravenous Posaconazole (MK-5592) in Chinese Participants at High Risk for Invasive Fungal Infections (MK-5592-120)
- First Posted Date
- 2017-11-08
- Last Posted Date
- 2019-12-19
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 70
- Registration Number
- NCT03336502
- Locations
- 🇨🇳
Institute of Hematology and Blood Diseases Hosp CAMS&PUMC ( Site 0001), Tianjin, China
🇨🇳Shanghai General Hospital ( Site 0007), Shanghai, China
🇨🇳Peking University Third Hospital ( Site 0009), Beijing, China
Posaconazole Prophylaxis During ATG Treatment for hMDS/AA Patients
- Conditions
- Interventions
- First Posted Date
- 2017-10-23
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- Seoul National University Hospital
- Target Recruit Count
- 20
- Registration Number
- NCT03318159
- Locations
- 🇰🇷
Seoul National University Hospital, Seoul, Korea, Republic of
Drug/Drug Interactions With F901318
- Conditions
- Interventions
- First Posted Date
- 2017-03-29
- Last Posted Date
- 2017-11-01
- Lead Sponsor
- F2G Biotech GmbH
- Registration Number
- NCT03095547
Registry of Patients Treated With Systemic Mold-Active Triazoles
- Conditions
- Interventions
- First Posted Date
- 2017-02-28
- Last Posted Date
- 2024-10-21
- Lead Sponsor
- Astellas Pharma Global Development, Inc.
- Target Recruit Count
- 2015
- Registration Number
- NCT03066011
- Locations
- 🇺🇸
Emory University, Atlanta, Georgia, United States
🇺🇸University of Arizona, Tucson, Arizona, United States
🇺🇸Stanford Health Care, Palo Alto, California, United States
Single Dose Population Pharmacokinetics of Intravenous Posaconazole in Critically Ill Patients
- First Posted Date
- 2016-11-18
- Last Posted Date
- 2018-09-21
- Lead Sponsor
- Royal Brisbane and Women's Hospital
- Target Recruit Count
- 8
- Registration Number
- NCT02968134
King's Invasive Aspergillosis Study II
- Conditions
- Interventions
- First Posted Date
- 2016-08-23
- Last Posted Date
- 2020-04-02
- Lead Sponsor
- King's College Hospital NHS Trust
- Target Recruit Count
- 120
- Registration Number
- NCT02875743
- Locations
- 🇬🇧
King's College Hospital NHS Foundation Trust, London, United Kingdom
Pharmacokinetics of Posaconazole (Noxafil®) as Prophylaxis for Invasive Fungal Infections
- Conditions
- Interventions
- First Posted Date
- 2016-06-20
- Last Posted Date
- 2019-12-16
- Lead Sponsor
- Radboud University Medical Center
- Target Recruit Count
- 21
- Registration Number
- NCT02805946
- Locations
- 🇳🇱
Radboudumc, Nijmegen, Netherlands
🇧🇪Universitaire Ziekenhuizen Leuven, Leuven, Belgium
Effect of Inflammation on Pharmacokinetics of Posaconazole
- First Posted Date
- 2015-07-09
- Last Posted Date
- 2019-08-06
- Lead Sponsor
- University Medical Center Groningen
- Target Recruit Count
- 64
- Registration Number
- NCT02492802
- Locations
- 🇳🇱
University Medical Center Groningen, Groningen, Netherlands
Pharmacokinetics and Safety of Oral Posaconazole (MK-5592)Tablets in Chinese Participants at High Risk for Invasive Fungal Infections (MK-5592-117)
- First Posted Date
- 2015-03-13
- Last Posted Date
- 2018-10-09
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 65
- Registration Number
- NCT02387983
Genetic Variation and Variability in Posaconazole Pharmacokinetics in Children
- First Posted Date
- 2015-02-09
- Last Posted Date
- 2020-12-22
- Lead Sponsor
- Children's Mercy Hospital Kansas City
- Target Recruit Count
- 31
- Registration Number
- NCT02358499
- Locations
- 🇺🇸
Children's Mercy Hospital Kansas City, Kansas City, Missouri, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.